Analysis Tools
mortality/aging
|
• no viable homozygotes are obtained due to preimplantation embryonic lethality
|
|
Allele Symbol Allele Name Allele ID |
Rnf20Gt(RRJ249)Byg gene trap RRJ249, BayGenomics MGI:4129198 |
||||||||||||
| Summary |
2 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• no viable homozygotes are obtained due to preimplantation embryonic lethality
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• heterozygotes develop more severe colon inflammation than wild-type controls by day 7 after dextran sodium sulfate (DSS, 2%) treatment; although inflammation is partially attenuated from day 65 onward, colonoscopy score is still higher than that in wild-type controls at day 180, indicating that heterozygotes are prone to both acute and chronic DSS-induced colonic inflammation
• DSS-treated heterozygotes show more abundant immune patches consisting of T cells, B cells and macrophages in their colons at day 65; more infiltrating macrophages (F4/80+), including M2 macrophages (CD206+), and more T cells (CD3+) are found at day 26 and 65 after DSS treatment
• inflamed colons from DSS-treated heterozygotes show stronger nuclear p65 staining and more abundant nuclear gamma-H2AX foci indicating, respectively, increased NF-kappa activity and DNA damage
|
|
|
• augmented splenomegaly at day 26 after DSS treatment
|
|
|
• increased spleen weight at day 26 and persisting up to day 180 after DSS treatment
|
|
|
• myeloid-derived suppressor cells (MDSCs) from DSS-treated heterozygotes are more active, producing excessive reactive oxygen species (ROS) and nitric oxide (NO) and overexpressing arginase 1, and have a greater capacity to downregulate T cell receptor zeta chain levels in co-incubated naive T cells
|
|
|
• splenic T cells from DSS-treated heterozygotes show downregulation of CD247 (T cell receptor zeta chain) within CD3+ cells, indicating impaired T cell function
• however, CD3 epsilon within CD3+ cells is normal, suggesting that reduced T cell functionality is mediated by MDSCs
|
|
|
• increased IFN-gamma secretion from thioglycollate-elicited peritoneal inflammatory leukocytes and bone marrow-derived macrophages after treatment with TNF-alpha
|
|
|
• increased TNF-alpha secretion from thioglycollate-elicited peritoneal inflammatory leukocytes and bone marrow-derived macrophages after treatment with TNF-alpha
|
|
|
• heterozygotes treated with AOM + DSS develop more polyps than similarly treated wild-type controls; adenomas often progress to carcinoma by day 180 after AOM + DSS treatment, unlike in wild-type controls
|
|
|
• several heterozygotes treated with DSS alone develop carcinomas by day 180 post-treatment, unlike DSS-treated wild-type controls
• some DSS-treated heterozygotes develop mucinous carcinoma with neoplastic glands invading the submucosa and penetrating the muscularis propria (T2 tumor stage), indicating an aggressive course
|
|
|
• heterozygotes injected with azoxymethane (AOM, 1 mg/g body weight) 7 days prior to DSS exposure develop more colorectal tumors than similarly treated wild-type controls
|
|
|
• increased weight loss in response to DSS treatment
|
|
|
• augmented splenomegaly at day 26 after DSS treatment
|
|
|
• increased spleen weight at day 26 and persisting up to day 180 after DSS treatment
|
|
|
• augmented splenomegaly at day 26 after DSS treatment
|
|
|
• increased spleen weight at day 26 and persisting up to day 180 after DSS treatment
|
|
|
• DSS-treated heterozygotes have significantly more myeloid-derived suppressor cells (MDSCs) than wild-type controls at day 26 after DSS treatment, as determined by IHC staining and FACS analysis of CD11b/GR1 positive cells
|
|
|
• myeloid-derived suppressor cells (MDSCs) from DSS-treated heterozygotes are more active, producing excessive reactive oxygen species (ROS) and nitric oxide (NO) and overexpressing arginase 1, and have a greater capacity to downregulate T cell receptor zeta chain levels in co-incubated naive T cells
|
|
|
• splenic T cells from DSS-treated heterozygotes show downregulation of CD247 (T cell receptor zeta chain) within CD3+ cells, indicating impaired T cell function
• however, CD3 epsilon within CD3+ cells is normal, suggesting that reduced T cell functionality is mediated by MDSCs
|
|
|
• myeloid-derived suppressor cells (MDSCs) from DSS-treated heterozygotes produce excessive nitric oxide
|
|
|
• heterozygotes injected with azoxymethane (AOM, 1 mg/g body weight) 7 days prior to DSS exposure develop more colorectal tumors than similarly treated wild-type controls
|
|
|
• MDSCs from DSS-treated mice produce excessive reactive oxygen species (ROS)
|
|
|
• shorter colons at day 65 and persisting up to day 180 after DSS treatment
|
|
|
• heterozygotes treated with AOM + DSS develop more polyps than similarly treated wild-type controls; adenomas often progress to carcinoma by day 180 after AOM + DSS treatment, unlike in wild-type controls
|
|
|
• several heterozygotes treated with DSS alone develop carcinomas by day 180 post-treatment, unlike DSS-treated wild-type controls
• some DSS-treated heterozygotes develop mucinous carcinoma with neoplastic glands invading the submucosa and penetrating the muscularis propria (T2 tumor stage), indicating an aggressive course
|
|
|
• increased fluorescence in the blood of mice force fed FITC-dextran, indicating compromised barrier function in the colon (intestinal leakiness)
|
|
|
• heterozygotes develop more severe colon inflammation than wild-type controls by day 7 after dextran sodium sulfate (DSS, 2%) treatment; although inflammation is partially attenuated from day 65 onward, colonoscopy score is still higher than that in wild-type controls at day 180, indicating that heterozygotes are prone to both acute and chronic DSS-induced colonic inflammation
• DSS-treated heterozygotes show more abundant immune patches consisting of T cells, B cells and macrophages in their colons at day 65; more infiltrating macrophages (F4/80+), including M2 macrophages (CD206+), and more T cells (CD3+) are found at day 26 and 65 after DSS treatment
• inflamed colons from DSS-treated heterozygotes show stronger nuclear p65 staining and more abundant nuclear gamma-H2AX foci indicating, respectively, increased NF-kappa activity and DNA damage
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 05/07/2024 MGI 6.23 |
|
|
|
||